RIDGELINE THERAPEUTICS LLC
Houston, TX · Biotech · Private
Small-molecule oral drug (RT-002) that inhibits NNMT enzyme to promote skeletal muscle regeneration and repair in aging adults
- Grants
- $7.8M
- 10 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Dose-ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetes | $299,972 | |
| Federal grant | Department of Health and Human Services · Phase I · Dose-ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetes | $299,972 | |
| Federal grant | Department of Health and Human Services · Phase I · Dose-ranging safety and efficacy studies to advance novel mechanism-of-action drug candidates to reverse age-related muscle degeneration | $357,630 | |
| Federal grant | Department of Health and Human Services · Phase I · Dose-ranging safety and efficacy studies to advance novel mechanism-of-action drug candidates to reverse age-related muscle degeneration | $357,630 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat Duchenne muscular dystrophy | $252,131 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat Duchenne muscular dystrophy | $252,131 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture | $3,966,288 | |
| Federal grant | Department of Health and Human Services · Phase I · A Novel Small Molecule Oral Therapeutic to Prevent and Reverse Skeletal Muscle Atrophy in Aging Adults | $322,432 | |
| Federal grant | Department of Health and Human Services · Phase I · A Novel Small Molecule Oral Therapeutic to Prevent and Reverse Skeletal Muscle Atrophy in Aging Adults | $322,432 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical validation of a novel adjunct small molecule drug to prevent muscle loss and enhance weight loss in older adults | $1,339,717 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1288 | Distributed Bio, Inc. | — | — |
| 1289 | PIPA LLC | — | — |
| 1290 | Aurora Oncology, Inc. | — | — |
| 1291 | RIDGELINE THERAPEUTICS LLC | — | — |
| 1292 | BIOORG3.14 LLC | — | — |
| 1293 | SUNOMIX THERAPEUTICS | — | — |
| 1294 | ImmunoTarget Therapeutics, Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.